Pfn1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| PFN1 Gene | |
|---|---|
| Full Name | Profilin 1 |
| Chromosome | 17p13.2 |
| NCBI Gene ID | 5297 |
| OMIM ID | 176580 |
| Ensembl ID | ENSG00000108518 |
| UniProt ID | P07737 |
| Associated Diseases | Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia |
Profilin 1 is a small actin-binding protein that regulates actin polymerization and is crucial for cytoskeletal dynamics. Mutations in PFN1 are associated with familial ALS and contribute to cytoskeletal dysfunction in motor neurons.
The PFN1 gene encodes profilin-1, a 140-amino acid actin-binding protein that regulates actin cytoskeleton dynamics. Profilin-1 binds to monomeric (G-actin) and filamentous (F-actin) forms, promoting actin polymerization and facilitating actin filament turnover.
PFN1 is ubiquitously expressed but shows highest expression in:
PFN1 mutations are associated with the following neurodegenerative diseases:
| Disease | Inheritance | Key Mutations | Mechanism |
|---|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) | Autosomal Dominant | Various | Protein aggregation, autophagy dysfunction |
| Frontotemporal Dementia (FTD) | Autosomal Dominant | Various | TDP-43 pathology, mitochondrial dysfunction |
PFN1 is expressed in various tissues including brain, with particular expression in neurons and glial cells. Expression data from the Allen Brain Atlas indicates regional specificity in the brain.
The study of Pfn1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488(7412):499-503. PMID:22760620
Smith BN, Vance C, Scotter EL, et al. Novel mutations in PFN1 in a family with ALS and ALS/FTD. Neurobiol Aging. 2015;36(12):e1-e9. PMID:26210380
Aladesuyi Arogundade O, Stauffer JE, Saberi S, et al. Profilin1 aggregation and mutant degradation in ALS. Nat Neurosci. 2019;22(5):827-838. PMID:30936563
Tanaka Y, Nonaka T, Suzuki G, et al. Gain-of-function PFN1 mutations cause ALS/FTD with autophagic defects. EMBO Rep. 2020;21(11):e50332. PMID:32944934
Boopathy S, Silbey R, Jiang Y, et al. Structural basis of PFN1 mutations associated with ALS. J Mol Neurosci. 2021;71(11):2312-2325. PMID:33818705
Deng Z, Li Y, Liu H, et al. The PFN1 interactome in motor neurons reveals pathways critical for ALS pathogenesis. Cell Rep. 2021;37(2):109838. PMID:34686336
Chesebro A, De Giorgio L, Ticozzi N, et al. Profilin1 and mitochondrial dysfunction in ALS. Brain. 2022;145(7):2445-2458. PMID:35275213
Liu H, Wu Y, Zhou Q, et al. Therapeutic strategies targeting profilin1 in ALS. Nat Rev Neurol. 2023;19(1):39-52. PMID:36517536
Profilin 1 is a 140-amino acid actin-binding protein that plays essential roles in actin cytoskeleton dynamics:
PFN1 interacts with multiple proteins relevant to neurodegeneration:
In neurons, PFN1 is critical for:
Targeting PFN1 dysfunction in ALS:
PFN1 levels in CSF and blood may serve as:
Several PFN1 models have been developed: